Genmab — April 2020
-
kkjoel...En fast abonnementordning havde vi frem til 2016. Vi kunne maks få 3-4.000 hjem på den ordning om året. Når jeg får Marthine tilbage ser vi om vi skal prøve igen.
-
Multiple myeloma: 2020 update on diagnosis, risk‐stratification and management https://onlinelibrary.wiley.com/doi/10.1002/ajh.25791
-
Monoclonal antibodies in multiple myeloma: Current and emerging targets and mechanisms of action https://www.sciencedirect.com/science/article/pii/S1521692620300049
-
BioNTech to commence first clinical trial of COVID-19 vaccine candidates https://www.streetinsider.com/Globe+Newswire/BioNTech+and+Pfizer+announce+regulatory+approval+from+German+authority+Paul-Ehrlich-Institut+to+commence+first+clinical+trial+of+COVID-19+vaccine+candidates/16769508.html
-
Hold da magle...1743 i lukauktion..indtil videre!!
-
Måske noget på vej????
-
OK..."kun" 1601,50
..:-) -
Mine tre største positioner i pharma er Genmab, Novo og J&J. De er næsten alle i ATH. Tålmodighed belønnes.
-
summary : Daratumumab was approved in Taiwan for the treatment of adult patients with relapsed and refractory multiple myeloma in 2017, and was included in the health insurance benefits in April 2020. https://udn.com/news/story/7266/4511829
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind